Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC).

被引：1
|
作者：
Balar, A. V.
Milowsky, M. I.
Apolo, A. B.
Ostrovnaya, I.
Iasonos, A.
Trout, A.
Regazzi, A. M.
Garcia-Grossman, I. R.
Gallagher, D. J.
Bajorin, D. F.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4566
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4566
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of gemcitabine, carboplatin, and bevacizumab in chemotherapy-naive patients (Pts) with advanced/metastatic urothelial carcinoma (UC)
    Balar, A. V.
    Milowsky, M. I.
    Apolo, A. B.
    Ostrovnaya, I.
    Iasonos, A.
    Trout, A.
    Regazzi, A. M.
    Garcia-Grossman, I. R.
    Gallagher, D. J.
    Bajorin, D. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [2] Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
    Balar, Arjun V.
    Apolo, Andrea B.
    Ostrovnaya, Irina
    Mironov, Svetlana
    Iasonos, Alexia
    Trout, Alisa
    Regazzi, Ashley M.
    Garcia-Grossman, Ilana R.
    Gallagher, David J.
    Milowsky, Matthew I.
    Bajorin, Dean F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) : 724 - 730
  • [3] Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC).
    Grivas, Petros
    Agarwal, Neeraj
    Siefker-Radtke, Arlene O.
    Daignault, Stephanie
    Puzanov, Igor
    MacVicar, Gary R.
    Levine, Ellis Glenn
    Srinivas, Sandy
    Twardowski, Przemyslaw
    Eisenberger, Mario A.
    Quinn, David I.
    Vaishampayan, Ulka N.
    Yu, Evan Y.
    Dawsey, Scott
    Day, Kathleen C.
    Day, Mark L.
    Smith, David C.
    Hussain, Maha
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Vascular thromboembolic events in patients (pts) with advanced urothelial cancer (UC) treated with carboplatin/gemcitabine alone or in combination with bevacizumab
    Apolo, A. B.
    Regazzi, A. M.
    Milowsky, M. I.
    Bajorin, D. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Carboplatin and gemcitabine in patients with advanced and/or metastatic urothelial cancers: A phase II study
    Baitar, Abdelbari
    De Vos, Machteld
    Vandebroek, An
    Schrijvers, Dirk
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2011, 2 (01) : 31 - 35
  • [6] Phase II trial of gemcitabine plus carboplatin for urothelial transitional cell carcinoma (UTCC) in advanced or metastatic stage
    Santoro, A
    Santoro, M
    Maiorino, L
    Forestieri, V
    Forestieri, P
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 169 - 169
  • [7] A phase I study of gemcitabine, carboplatin, and lenalidomide for treatment of patients with advanced/metastatic urothelial carcinoma (UC) and other solid tumors
    Apolo, Andrea Borghese
    Parnes, Howard L.
    Madan, Ravi Amrit
    Gulley, James L.
    Trepel, Jane B.
    Lee, Min-Jung
    Lee, Sunmin
    Steinberg, Seth M.
    John, Simone
    Velasco, Sylvia Vania Alarcon
    Figg, William Douglas
    Dahut, William L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Phase II study of gemcitabine, cisplatin and sunitinib in patients with advanced urothelial carcinoma (UC).
    Galsky, M. B.
    Sonpavde, G.
    Hellerstedt, B. A.
    McKenney, S. A.
    Hutson, T. E.
    Rauch, M. A.
    Wang, Y.
    Boehm, K. A.
    Asmar, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Hcrn GU15-215: A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC).
    Balar, Arjun Vasant
    Funt, Samuel Aaron
    Gupta, Shilpa
    Dudek, Arkadiusz Z.
    Boiles, Alejandro Recio
    Vaena, Daniel A.
    Kilari, Deepak
    Rosenberg, Jonathan E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM).
    Lin, Nancy U.
    Gelman, Rebecca Sue
    Younger, W. Jerry
    Sohl, Jessica
    Freedman, Rachel A.
    Sorensen, A. Gregory
    Bullitt, Elizabeth
    Harris, Gordon J.
    Morganstern, Daniel
    Schneider, Bryan P.
    Krop, Ian E.
    Winer, Eric P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345